Medicare Enrolled
Dr. Shamim Jilani, MD
Medical Oncology · Dayton, OH
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Jilani from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Jilani?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Jilani
Dr. Shamim Jilani is a medical oncology specialist in Dayton, OH, with 20 years of NPI registration. Based on federal Medicare data, Dr. Jilani performed 35,027 Medicare services across 1,015 unique beneficiaries.
Between the years covered by Open Payments, Dr. Jilani received a total of $6,284 from 66 pharmaceutical and/or device companies across 397 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Jilani is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 12% volume in OH
$6,284 industry payments
Medicare Practice Summary
Medicare Utilization ↗35,027
Medicare services
Top 12% in OH for medical oncology
1,015
Unique beneficiaries
$15
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,751 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
8,550 | $0 | $1 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
7,520 | $2 | $8 |
| Pembrolizumab injection (Keytruda) | 6,200 | $43 | $99 |
| Denosumab injection (Prolia/Xgeva) | 5,160 | $18 | $37 |
| Contrast dye for imaging (iodine-based) A contrast agent containing 300-399 mg/ml of iodine used to enhance imaging studies. It is administered per milliliter to improve the visibility of internal structures. |
2,800 | $0 | $0 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,314 | $0 | $0 |
| Anti-nausea injection (Aloxi/palonosetron) | 720 | $1 | $3 |
| Injection, leucovorin calcium, per 50 mg | 443 | $3 | $11 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
358 | $2 | $5 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
349 | $85 | $207 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
217 | $95 | $403 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
185 | $11 | $64 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
175 | $56 | $140 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
170 | $10 | $45 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
104 | $53 | $155 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
82 | $21 | $100 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
78 | $7 | $50 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
73 | $1 | $1 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
67 | $47 | $198 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
62 | $21 | $92 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
58 | $85 | $156 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
57 | $45 | $181 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
45 | $41 | $166 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
38 | $15 | $61 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
37 | $56 | $110 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
30 | $128 | $313 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
29 | $130 | $281 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
29 | $1 | $4 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 26 | $627 | $800 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
25 | $771 | $2,196 |
| CT scan of chest with contrast A computed tomography scan of the chest using a contrast dye to enhance the visibility of internal structures. |
14 | $84 | $470 |
| New patient office visit, complex (60-74 min) | 12 | $129 | $402 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.3% high complexity
96.7% medium
2.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$6,284
Total received (2018-2024)
Avg $898/year across 7 years
Top 36% in OH for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
66
Companies
397
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,708 (90.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$577 (9.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$916
2023
$1,658
2022
$1,034
2021
$420
2020
$133
2019
$1,093
2018
$1,030
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Merck Sharp & Dohme LLC
$184
E.R. Squibb & Sons, L.L.C.
$65
Novartis Pharmaceuticals Corporation
$65
GlaxoSmithKline, LLC.
$61
Kyowa Kirin, Inc.
$58
ABBVIE INC.
$54
Janssen Biotech, Inc.
$51
PFIZER INC.
$46
AstraZeneca Pharmaceuticals LP
$44
Daiichi Sankyo Inc.
$42
Regeneron Healthcare Solutions, Inc.
$38
JAZZ PHARMACEUTICALS INC.
$30
Kite Pharma, Inc.
$29
Genmab U.S., Inc.
$23
Aveo Pharmaceuticals, Inc.
$21
Ipsen Biopharmaceuticals, Inc
$20
Amneal Pharmaceuticals LLC
$19
Genentech USA, Inc.
$18
Celgene Corporation
$16
Gilead Sciences, Inc.
$15
SpringWorks Therapeutics, Inc.
$15
Top 3 companies account for 34.3% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$751
Janssen Biotech, Inc.
$623
Merck Sharp & Dohme LLC
$433
E.R. Squibb & Sons, L.L.C.
$430
PFIZER INC.
$423
Pharmacyclics LLC, An AbbVie Company
$346
Daiichi Sankyo Inc.
$285
Celgene Corporation
$203
AstraZeneca Pharmaceuticals LP
$188
Amgen Inc.
$166
GENZYME CORPORATION
$153
Astellas Pharma US Inc
$136
Regeneron Healthcare Solutions, Inc.
$126
EISAI INC.
$105
Boehringer Ingelheim Pharmaceuticals, Inc.
$101
GlaxoSmithKline, LLC.
$90
Kyowa Kirin, Inc.
$81
Takeda Pharmaceuticals U.S.A., Inc.
$81
Bayer HealthCare Pharmaceuticals Inc.
$80
Merck Sharp & Dohme Corporation
$74
Kite Pharma, Inc.
$69
Gilead Sciences, Inc.
$67
Foundation Medicine, Inc.
$60
Incyte Corporation
$60
Seagen Inc.
$58
Ipsen Biopharmaceuticals, Inc
$56
Pharmacyclics LLC, an AbbVie Company
$55
ABBVIE INC.
$54
Genentech USA, Inc.
$54
Puma Biotechnology, Inc.
$54
TerSera Therapeutics LLC
$51
Eisai Inc.
$50
Lilly USA, LLC
$48
JAZZ PHARMACEUTICALS INC.
$44
Bayer Healthcare Pharmaceuticals Inc.
$39
Janssen Scientific Affairs, LLC
$38
Teva Pharmaceuticals USA, Inc.
$30
Rigel Pharmaceuticals, Inc.
$29
MorphoSys, US Inc.
$25
Janssen Pharmaceuticals, Inc
$24
Genmab U.S., Inc.
$23
Stemline Therapeutics Inc.
$23
SERVIER PHARMACEUTICALS LLC
$22
TESARO, Inc.
$22
Adaptive Biotechnologies Corporation
$22
Karyopharm Therapeutics Inc.
$21
Alnylam Pharmaceuticals Inc.
$21
Aveo Pharmaceuticals, Inc.
$21
Amneal Pharmaceuticals LLC
$19
AVEO Pharmaceuticals, Inc.
$18
ADC Therapeutics America, Inc.
$18
Alexion Pharmaceuticals, Inc.
$18
MENARINI SILICON BIOSYSTEMS, INC.
$18
SOBI, INC
$18
Taiho Oncology, Inc.
$17
BeiGene USA, Inc.
$16
Heron Therapeutics, Inc.
$15
SpringWorks Therapeutics, Inc.
$15
Sun Pharmaceutical Industries Inc.
$15
PUMA BIOTECHNOLOGY, INC.
$15
ARRAY BIOPHARMA INC
$14
Epizyme, Inc.,
$12
Clovis Oncology, Inc.
$12
Dova Pharmaceuticals
$11
Exelixis Inc.
$11
AbbVie, Inc.
$11
Top 3 companies account for 28.8% of all-time payments
Associated products mentioned in payments ›
AFINITOR · ALUNBRIG · AVASTIN · Aliqopa · BENDEKA · BOSULIF · BRAFTOVI · BRUKINSA · CABLIVI · CABOMETYX · CALQUENCE · CINVANTI · Cellsearch · DARZALEX · Doptelet · ELIQUIS · ELITEK · EMPLICITI · ENHERTU · EPKINLY · ERBITUX · ERLEADA · Enhertu · Epkinly · Erleada · FOTIVDA · FOUNDATIONONE · Fabhalta · GILOTRIF · GIVLAARI · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · JADENU · JAKAFI · JEMPERLI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LYNPARZA · Lenvima · Lunsumio · MEKINIST · MONJUVI · MYLOTARG · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OGSIVEO · OJJAARA · OPDIVO · OPDUALAG · OXBRYTA · Onivyde · Orserdu · PADCEV · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · Phesgo · Pomalyst · Poteligeo · REBLOZYL · Rezlidhia · Rubraca · SANDOSTATIN LAR · SCEMBLIX · SHINGRIX · SOMATULINE DEPOT · SPRYCEL · SUTENT · Stivarga · TABRECTA · TASIGNA · TAZVERIK · TECVAYLI · Tavalisse · Tibsovo · ULTOMIRIS · VENCLEXTA · VERZENIO · VOTRIENT · VYXEOS · Venclexta · XALKORI · XPOVIO · XTANDI · Xermelo · Xofigo · YONSA (abiraterone acetate) · Yescarta · ZEJULA · ZEPZELCA · ZOLADEX
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (91%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Medical oncologists within 10 mi
7
Per 100K population
1.3
County median income
$64,403
Nearest hospital
KETTERING HEALTH DAYTON
3.7 mi
3.7 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Jilani is a mixed practice specialist, with above-average Medicare volume (top 12% in OH), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Jilani experienced with anti-nausea injection (fosaprepitant)?
Based on Medicare claims data, Dr. Jilani performed 8,550 anti-nausea injection (fosaprepitant) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Jilani receive payments from pharmaceutical companies?
Yes. Dr. Jilani received a total of $6,284 from 66 companies across 397 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Jilani's costs compare to other medical oncologists in Dayton?
Dr. Jilani's average Medicare payment per service is $15. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Jilani) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Dayton
Browse medical oncologists in Dayton ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in OH
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in OH
Which OH medical oncologists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
Merck Sharp & Dohme LLC Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology